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Most tumors display enhanced glucose metabolism com-
pared to normal tissues [1-6]. The preferential conversion
of glucose to lactate in cancer cells (the Warburg Effect)
was one of the first known differences between tumor
a n dn o r m a lc e l l sa n di sb e l i e v e dt oc o n t r i b u t et o
enhanced growth in tumor cells. However, the extent to
which specific metabolic fluxes originating from glucose
branch from central carbon metabolism and are utilized
for anabolic processes is poorly understood. Here, we
used an integrated, quantitative metabolomics approach
combining NMR experiments with heavy isotope labeling
and targeted mass-spectrometry. We carried out direct
measurements of metabolic fluxes emanating from
glucose metabolism [7].
W ef o u n dt h a ti ns o m ec a n c e rc ells, a relatively large
amount of glycolytic carbon was diverted into serine and
glycine biosynthesis. Serine can be synthesized from a gly-
colytic intermediate, 3-phosphoglycerate (3PG). 3PG is
oxidized by an enzyme phosphoglycerate dehydrogenase
(PHGDH) in an NAD-dependent manner to generate
phosphohydroxypyruvate which is transaminated and then
dephosphorylated to generate serine. Serine hydroxy-
methyltransferase then donates the side-chain of serine to
the Folate pool to generate glycine.
We quantified the relative amount of glycolytic flux
being diverted into serine and glycine biosynthesis and
found that it was comparable to the amount of glucose
passing through glycolysis and ultimately being converted
to lactate. However, this large flux was observed to be pre-
sent in only a subset of cultured cells. A non-tumorigenic
breast epithelial cell line was found to have no detectable
flux into serine and glycine biosynthesis. The observation
that some but not all cancer cells divert a large amount of
glycolytic flux into serine and glycine metabolism sug-
gested that there might be a context in which this flux
might be selected for in the development of cancer.
To search for this context, we investigated a pooled ana-
lysis of 3131 human cancers [8]. This analysis revealed
t h a tP H G D H ,t h eg e n et h a te n c o d e st h ef i r s te n z y m ei n
this biosynthetic pathway branching off of glycolysis is fre-
quently present in a region of recurrent, localized copy
number gain at genomic locus 1p12 (q=1.18e-9). The
amplification was most commonly found in melanoma but
was observed in other cancers such as eosophageal adeno-
carcinoma and triplenegative breast cancer. We validated
this finding in a collection of human melanoma tissue
samples by comparing PHGDH expression in human tis-
sues as measured by Immunohistochemistry with matched
assessments of PHGDH copy number gain using fluores-
cence in situ hybridization. It was observed that PHGDH
protein expression correlated with genomic copy number
gain.
To assess whether cells containing the amplification
were differentially sensitive to inhibition of PHGDH
expression, we considered a panel of tumor-derived
human Melanoma cell lines. Each melanoma cell line with
PGHDH amplification exhibited significant flux into serine
biosynthesis. We then carried out an RNA interference
study and found that decreased PHGDH expression by
RNA interference impaired growth in cell lines containing
amplification of PHGDH and resulted in a distinct meta-
bolic phenotype marked by accumulation of glycolytic
intermediates.
PHGDH expression was also found to be associated
with aggressive breast cancer subtypes. Since we observed
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cell line, we questioned whether enhanced PHGDH
expression would have any phenotypic consequences.
We considered the effects of PHGDH in a model of
breast tissue morphogenesis [9]. In this model, ectopic
expression of PHGDH in MCF10A cells induced loss of
cell polarity, disruptions in nuclear architecture and rescue
of anoikis – each being phenotypic alterations that predis-
pose cells to tumorgenicity. Our findings demonstrate that
altered metabolic flux stemming from glycolysis can be
selected for in the development of cancer and contribute
to cell transformation. Furthermore, our studies identify
PHGDH as an attractive therapeutic target for subsets of
human cancers.
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